
2ND HEART is a biotechnology company focused on developing precision medicine strategies in cardiovascular diseases. Their core offering is an award-winning clinical simulator powered by advanced AI, which provides precise, fast, and predictive analysis of patient-specific cardiovascular data. This simulation aims to define optimal therapeutic implications for individual patients, particularly for valvular pathologies, offering deep quantitative and qualitative insights into valvular biomechanics. The company leverages multidisciplinary approaches including Tissue-Engineering, Fluorescence Spectroscopy, Bioinformatics, and Computer Science. Their vision is to significantly reduce mortality rates associated with procedures like valvuloplasty and TAVR, transforming clinical decision-making and improving patient outcomes.

2ND HEART is a biotechnology company focused on developing precision medicine strategies in cardiovascular diseases. Their core offering is an award-winning clinical simulator powered by advanced AI, which provides precise, fast, and predictive analysis of patient-specific cardiovascular data. This simulation aims to define optimal therapeutic implications for individual patients, particularly for valvular pathologies, offering deep quantitative and qualitative insights into valvular biomechanics. The company leverages multidisciplinary approaches including Tissue-Engineering, Fluorescence Spectroscopy, Bioinformatics, and Computer Science. Their vision is to significantly reduce mortality rates associated with procedures like valvuloplasty and TAVR, transforming clinical decision-making and improving patient outcomes.